ARRAY BIOPHARMA ($ARRY) posted quarterly earnings results on Tuesday, May 6th. The company reported earnings of $0.13 per share, beating estimates of $0.09 by $0.04 ...

Array BioPharma (Nasdaq: ARRY) today reported top-line results from the ongoing Phase 3 clinical trial of binimetinib in patients with advanced NRAS-mutant melanoma, known as the NEMO trial. The study ...

Array BioPharma Inc. (NASDAQ: ARRY) today reported results for the fourth quarter and full year of its fiscal year ended June 30, 2015. Ron Squarer, Chief Executive Officer of Array, noted, ...

Unfortunately you've used all of your gifts this month. Your counter will reset on the first day of next month. Overall, the long-term thesis for owning Array's stock continues to look intact. If you ...

The following slide deck was published by Array BioPharma Inc. in conjunction with this event.

Oncothyreon Inc. and Array BioPharma Inc. have announced the initiation of a Phase 1b trial of ONT-380 (ARRY-380) in combination with Kadcyla® (ado-trastuzumab emtansine or TDM-1) in patients with ...

Following Array Biopharma Inc (NASDAQ:ARRY) reporting positive top line results from part 2 of a late-stage study of its combo treatment candidate for metastatic and BRAF-mutant melanoma, Leerink ...

* Array Biopharma -on December 22, 2016 entered into loan and security agreement providing for revolving line of credit of up to $5 million * Array Biopharma Inc - loan agreement also provides for ...

Pfizer Inc and Array BioPharma Inc announced that they have entered into a definitive merger agreement under which Pfizer will acquire Array, a commercial stage biopharmaceutical company focused on ...

Success in trials of new drugs for metastatic melanoma propelled the stock of Array Biopharma (NASDAQ: ARRY) 115% in 2016. However, after a string of successes, Array hit a setback earlier this week: ...

NEW YORK (Reuters) - Array BioPharma Inc on Thursday sued AstraZeneca AB , accusing the pharmaceutical company of refusing to pay required royalties for a cancer drug after entering into an $8.5 ...

To continue reading this content, please enable JavaScript in your browser settings and refresh this page. The Dow and Nasdaq finished January trading with a mixed ...